This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Ho, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Ho, D. D.

 Previous Article  |  Next Article 

Journal of Virology, March 2005, p. 2678-2688, Vol. 79, No. 5
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.5.2678-2688.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

Zhiwei Chen,1*,{dagger} Linqi Zhang,1,{dagger} Chuan Qin,2,{dagger} Lei Ba,1 Christopher E. Yi,1 Fengwen Zhang,1 Qiang Wei,2 Tian He,1 Wenjie Yu,1 Jian Yu,1 Hong Gao,2 Xinming Tu,2 Agegnehu Gettie,1 Michael Farzan,3 Kwok-yung Yuen,4 and David D. Ho1*

Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York,1 Department of Microbiology, University of Hong Kong, Hong Kong,4 Institute of Laboratory Animal Science, Chinese Academy of Medical Science, Beijing, People's Republic of China,2 Partners AIDS Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3

Received 9 July 2004/ Accepted 13 October 2004

Immunization with a killed or inactivated viral vaccine provides significant protection in animals against challenge with certain corresponding pathogenic coronaviruses (CoVs). However, the promise of this approach in humans is hampered by serious concerns over the risk of leaking live severe acute respiratory syndrome (SARS) viruses. In this study, we generated a SARS vaccine candidate by using the live-attenuated modified vaccinia virus Ankara (MVA) as a vector. The full-length SARS-CoV envelope Spike (S) glycoprotein gene was introduced into the deletion III region of the MVA genome. The newly generated recombinant MVA, ADS-MVA, is replication incompetent in mammalian cells and highly immunogenic in terms of inducing potent neutralizing antibodies in mice, rabbits, and monkeys. After two intramuscular vaccinations with ADS-MVA alone, the 50% inhibitory concentration in serum was achieved with reciprocal sera dilutions of more than 1,000- to 10,000-fold in these animals. Using fragmented S genes as immunogens, we also mapped a neutralizing epitope in the region of N-terminal 400 to 600 amino acids of the S glycoprotein (S400-600), which overlaps with the angiotensin-converting enzyme 2 (ACE2) receptor-binding region (RBR; S318-510). Moreover, using a recombinant soluble RBR-Fc protein, we were able to absorb and remove the majority of the neutralizing antibodies despite observing that the full S protein tends to induce a broader spectrum of neutralizing activities in comparison with fragmented S proteins. Our data suggest that a major mechanism for neutralizing SARS-CoV likely occurs through blocking the interaction between virus and the cellular receptor ACE2. In addition, ADS-MVA induced potent immune responses which very likely protected Chinese rhesus monkeys from pathogenic SARS-CoV challenge.


* Corresponding author. Mailing address: Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016. Phone: (212) 448-5031. Fax: (212) 725-1126. E-mail for Z. Chen: zchen{at}adarc.org. E-mail for D. Ho: dho{at}adarc.org.

{dagger} Z.C., L.Z., and C.Q. contributed equally to this study.


Journal of Virology, March 2005, p. 2678-2688, Vol. 79, No. 5
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.5.2678-2688.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Du, L., Zhao, G., Lin, Y., Sui, H., Chan, C., Ma, S., He, Y., Jiang, S., Wu, C., Yuen, K.-Y., Jin, D.-Y., Zhou, Y., Zheng, B.-J. (2008). Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection. J. Immunol. 180: 948-956 [Abstract] [Full Text]  
  • Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., Yuen, K. Y. (2007). Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection. Clin. Microbiol. Rev. 20: 660-694 [Abstract] [Full Text]  
  • Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L. E., Prabakaran, P., Rockx, B., Sidorov, I. A., Corti, D., Vogel, L., Feng, Y., Kim, J.-O., Wang, L.-F., Baric, R., Lanzavecchia, A., Curtis, K. M., Nabel, G. J., Subbarao, K., Jiang, S., Dimitrov, D. S. (2007). Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 104: 12123-12128 [Abstract] [Full Text]  
  • DiNapoli, J. M., Kotelkin, A., Yang, L., Elankumaran, S., Murphy, B. R., Samal, S. K., Collins, P. L., Bukreyev, A. (2007). Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. USA 104: 9788-9793 [Abstract] [Full Text]  
  • Liu, L., Fang, Q., Deng, F., Wang, H., Yi, C. E., Ba, L., Yu, W., Lin, R. D., Li, T., Hu, Z., Ho, D. D., Zhang, L., Chen, Z. (2007). Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus. J. Virol. 81: 4694-4700 [Abstract] [Full Text]  
  • Shih, Y.-P., Chen, C.-Y., Liu, S.-J., Chen, K.-H., Lee, Y.-M., Chao, Y.-C., Chen, Y.-M. A. (2006). Identifying Epitopes Responsible for Neutralizing Antibody and DC-SIGN Binding on the Spike Glycoprotein of the Severe Acute Respiratory Syndrome Coronavirus.. J. Virol. 80: 10315-10324 [Abstract] [Full Text]  
  • Gillim-Ross, L., Subbarao, K. (2006). Emerging Respiratory Viruses: Challenges and Vaccine Strategies. Clin. Microbiol. Rev. 19: 614-636 [Abstract] [Full Text]  
  • Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., Dimitrov, D. S. (2006). Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody. J. Biol. Chem. 281: 15829-15836 [Abstract] [Full Text]  
  • He, Y., Li, J., Heck, S., Lustigman, S., Jiang, S. (2006). Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design.. J. Virol. 80: 5757-5767 [Abstract] [Full Text]  
  • He, Y., Li, J., Li, W., Lustigman, S., Farzan, M., Jiang, S. (2006). Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein. J. Immunol. 176: 6085-6092 [Abstract] [Full Text]  
  • Li, W., Wong, S.-K., Li, F., Kuhn, J. H., Huang, I-C., Choe, H., Farzan, M. (2006). Animal Origins of the Severe Acute Respiratory Syndrome Coronavirus: Insight from ACE2-S-Protein Interactions. J. Virol. 80: 4211-4219 [Full Text]  
  • Yi, C. E., Ba, L., Zhang, L., Ho, D. D., Chen, Z. (2005). Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain. J. Virol. 79: 11638-11646 [Abstract] [Full Text]